- Home
- GNLX vs IMAB Comparison
GNLX vs IMAB Comparison
Compare GNLX & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- IMAB
- Stock Information
- Founded
- GNLX 2001
- IMAB 2014
- Country
- GNLX United States
- IMAB United States
- Employees
- GNLX N/A
- IMAB N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- GNLX Health Care
- IMAB Health Care
- Exchange
- GNLX Nasdaq
- IMAB Nasdaq
- Market Cap
- GNLX 128.0M
- IMAB 384.6M
- IPO Year
- GNLX 2023
- IMAB 2020
- Fundamental
- Price
- GNLX $4.01
- IMAB $3.65
- Analyst Decision
- GNLX Strong Buy
- IMAB Strong Buy
- Analyst Count
- GNLX 4
- IMAB 5
- Target Price
- GNLX $17.75
- IMAB $6.80
- AVG Volume (30 Days)
- GNLX 153.6K
- IMAB 1.7M
- Earning Date
- GNLX 11-13-2025
- IMAB 11-02-2025
- Dividend Yield
- GNLX N/A
- IMAB N/A
- EPS Growth
- GNLX N/A
- IMAB N/A
- EPS
- GNLX N/A
- IMAB N/A
- Revenue
- GNLX N/A
- IMAB N/A
- Revenue This Year
- GNLX N/A
- IMAB N/A
- Revenue Next Year
- GNLX N/A
- IMAB N/A
- P/E Ratio
- GNLX N/A
- IMAB N/A
- Revenue Growth
- GNLX N/A
- IMAB N/A
- 52 Week Low
- GNLX $1.95
- IMAB $0.60
- 52 Week High
- GNLX $5.89
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- GNLX 61.95
- IMAB 44.80
- Support Level
- GNLX $3.76
- IMAB $3.20
- Resistance Level
- GNLX $4.21
- IMAB $4.64
- Average True Range (ATR)
- GNLX 0.26
- IMAB 0.38
- MACD
- GNLX 0.05
- IMAB -0.16
- Stochastic Oscillator
- GNLX 78.02
- IMAB 30.20
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).